Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
Gene expression and miRNA data analysis
Automated analytical pipelines that are modular and flexible, combined with the use of...
How to ensure lab compliance and maximise your productivity
[Infographic] Transform your lab in the cloud |...
The solution for a seamless quantitative bioanalysis
High selectivity is a critical element of successful quantitative bioanalysis. Recent...
